226 related articles for article (PubMed ID: 11748189)
1. Bacterial lipoprotein-based vaccines induce tumor necrosis factor-dependent type 1 protective immunity against Leishmania major.
Cote-Sierra J; Bredan A; Toldos CM; Stijlemans B; Brys L; Cornelis P; Segovia M; de Baetselier P; Revets H
Infect Immun; 2002 Jan; 70(1):240-8. PubMed ID: 11748189
[TBL] [Abstract][Full Text] [Related]
2. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis.
Walker PS; Scharton-Kersten T; Rowton ED; Hengge U; Bouloc A; Udey MC; Vogel JC
Hum Gene Ther; 1998 Sep; 9(13):1899-907. PubMed ID: 9741428
[TBL] [Abstract][Full Text] [Related]
3. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.
Coler RN; Skeiky YA; Bernards K; Greeson K; Carter D; Cornellison CD; Modabber F; Campos-Neto A; Reed SG
Infect Immun; 2002 Aug; 70(8):4215-25. PubMed ID: 12117930
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N; Seder RA
J Exp Med; 1997 Oct; 186(7):1137-47. PubMed ID: 9314562
[TBL] [Abstract][Full Text] [Related]
5. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response.
Handman E; Symons FM; Baldwin TM; Curtis JM; Scheerlinck JP
Infect Immun; 1995 Nov; 63(11):4261-7. PubMed ID: 7591056
[TBL] [Abstract][Full Text] [Related]
6. MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis.
Pérez-Jiménez E; Kochan G; Gherardi MM; Esteban M
Microbes Infect; 2006 Mar; 8(3):810-22. PubMed ID: 16504562
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
[TBL] [Abstract][Full Text] [Related]
8. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
[TBL] [Abstract][Full Text] [Related]
9. Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection.
Rivier D; Bovay P; Shah R; Didisheim S; Mauël J
Parasite Immunol; 1999 Sep; 21(9):461-73. PubMed ID: 10476055
[TBL] [Abstract][Full Text] [Related]
10. Comparative Assessment of Induced Immune Responses Following Intramuscular Immunization with Fusion and Cocktail of LeIF, LACK and TSA Genes Against Cutaneous Leishmaniasis in BALB/c Mice.
Maspi N; Ghaffarifar F; Sharifi Z; Dalimi A; Dayer MS
Arch Immunol Ther Exp (Warsz); 2018 Feb; 66(1):55-64. PubMed ID: 28779346
[TBL] [Abstract][Full Text] [Related]
11. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge.
Méndez S; Gurunathan S; Kamhawi S; Belkaid Y; Moga MA; Skeiky YA; Campos-Neto A; Reed S; Seder RA; Sacks D
J Immunol; 2001 Apr; 166(8):5122-8. PubMed ID: 11290794
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
Iborra S; Soto M; Carrión J; Alonso C; Requena JM
Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
[TBL] [Abstract][Full Text] [Related]
13. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
Bhowmick S; Ravindran R; Ali N
Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029
[TBL] [Abstract][Full Text] [Related]
14. Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice.
Jaafari MR; Ghafarian A; Farrokh-Gisour A; Samiei A; Kheiri MT; Mahboudi F; Barkhordari F; Khamesipour A; McMaster WR
Vaccine; 2006 Jul; 24(29-30):5708-17. PubMed ID: 16740346
[TBL] [Abstract][Full Text] [Related]
15. Targeting Leishmania major Antigens to Dendritic Cells In Vivo Induces Protective Immunity.
Matos I; Mizenina O; Lubkin A; Steinman RM; Idoyaga J
PLoS One; 2013; 8(6):e67453. PubMed ID: 23840706
[TBL] [Abstract][Full Text] [Related]
16. Activation of skin dendritic cells by immunostimulatory DNA.
Vogel JC; Udey MC
Springer Semin Immunopathol; 2000; 22(1-2):45-54. PubMed ID: 10944799
[No Abstract] [Full Text] [Related]
17. Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection.
Sjölander A; Baldwin TM; Curtis JM; Bengtsson KL; Handman E
Vaccine; 1998 Dec; 16(20):2077-84. PubMed ID: 9796067
[TBL] [Abstract][Full Text] [Related]
18. Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.
Salay G; Dorta ML; Santos NM; Mortara RA; Brodskyn C; Oliveira CI; Barbiéri CL; Rodrigues MM
Clin Vaccine Immunol; 2007 Sep; 14(9):1173-81. PubMed ID: 17626159
[TBL] [Abstract][Full Text] [Related]
19. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.
Afonso LC; Scharton TM; Vieira LQ; Wysocka M; Trinchieri G; Scott P
Science; 1994 Jan; 263(5144):235-7. PubMed ID: 7904381
[TBL] [Abstract][Full Text] [Related]
20. Recombinant BCG expressing the leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice.
Abdelhak S; Louzir H; Timm J; Blel L; Benlasfar Z; Lagranderie M; Gheorghiu M; Dellagi K; Gicquel B
Microbiology (Reading); 1995 Jul; 141 ( Pt 7)():1585-92. PubMed ID: 7551026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
